Introduction. Studies performed on PsA showed a unique disease burden driven by its varied pathophysiological manifestations. Material and methods. A descriptive study was conducted by selecting patients in a group of 46 subjects with the diagnosis of psoriatic arthritis. The aim was to assess the burden of the disease valued by PSAID-12 verifying its interpretability in clinical practice by the relationship with other psoriatic measures. The PsA measures were assessed by DAPSA (Disease Activity in Psoriatic Arthritis), Psoriasis Area Severity Index (PASI), Health Assessment Questionnaire (HAQ) for physical function, SF-8 for Quality of life, and PSAID-12 for the burden of the disease. Results. Data reveal the mean ± SD disease activity according to the DAPSA index of 27.33 ± 15.76 points with wide v.i. range (9.2 - 74.6 p.). PASI was predominating with moderate values in 30 (65.22%) patients. The SF-8 mental and physical domain mean values of 40.72 and 43.04 were estimated for the quality of life. The HAQ questionnaire determined the mean value of 0.61±0.48 (v.i.0-1.4 p.). PSAID revealed the positivity of all twelve items. The most common parameters were coping (7.6 p), anxiety (8 p), and embarrassment (9.1 p). The strongest correlation of PSAID was found with disease activity (r=0.64, p<0.05), followed by HAQ (r=0.59 p<0.05) and mental status of quality of life (r=0.57 p<0.05). Conclusion. The impact of the disease assessed by PsAID was influenced by both physical and mental components of the patient’s quality of life, correlating with psoriatic arthritis indices and confirming the reliability of this tool.